Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase

Journal of Viral Hepatitis

Volumn 15, Issue 8, 2008, Pages 571-577

  Ward, C L ^a   Dev, A ^b   Rigby, S ^a   Symonds, W T ^c   Patel, K ^b   Zekry, A ^b   Pawlotsky, J M ^d,e   McHutchison, J G ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d HENRI MONDOR HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Guanosine analogue; Interferon; Mutagenesis; Ribavirin; RNA polymerase

Indexed keywords

ALPHA2B INTERFERON; NONSTRUCTURAL PROTEIN 5; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MUTATION; RIBAVIRIN; RNA REPLICASE; SELECTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 64549127857     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00980.x     Document Type: Article

References (30)

1. Pawlotsky JM, Dahari H, Neumann AU et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-714.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon a-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Young KC, Lindsay KL, Lee KJ et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003; 38: 869-878.
5. Vrolijk JM, Kaul A, Hansen BE et al. A replicon-based bio- assay for the measurement of interferons in patients with chronic hepatitis C. J Virol Meth 2003; 110: 201-209.
6. Ronaghi M. Improved performance of pyrosequencing using single-stranded DNA-binding protein. Anal Biochem 2000; 286: 282-288.
7. Le Pogam S, Dubois F, Christen R, Raby C, Cavicchini A, Goudeau A. Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping. J Clin Microbiol 1998; 36: 1461-1463.
8. Hofmann WP, Polta A, Herrmann E et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007; 132: 921-930.
9. Lutchman G, Danehower S, Song BC et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007; 132: 1757-1766.
10. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007; 81: 7732-7741.
11. Tarn RC, Pai B, Bard J et al. Ribavirin polarizes human T-cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376-382.
12. Hultgren C, Milich DR, Weiland 0, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381-2391.
13. Tsai SL, Liaw YR, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-458.
14. McHutchison JG, Shiffman ML, Cheung RC et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-α in previously untreated patients with chronic hepatitis C. Antivir Ther 2005; 10: 635-643.
15. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058- 1061.
16. Di Bisceglie AM, Shindo M, Fong T-L et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.
17. Reichard 0, Yun Z-B, Sonnerborg A, Weiland 0. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99-102.
18. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-598.
19. McHutchison JG, Gordon SC, Schiff ER et al. Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485- 1492.
20. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 52: 1426-1432.
21. Herrmann E, Lee J-H, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351- 1358.
22. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 2005; 79: 2346-2355.
23. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003; 311: 339-349.
24. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77: 481-488.
25. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, Morrey JD. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 2005; 67: 38-45.
26. Lanford RE, Chavez D, Guerra B et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001; 75: 8074-8081.
27. Leyssen P, De Clerq E, Neyts J. The anti-Yellow Fever virus activity of ribavirin is independent of error-prone replication. Mol Pharm 2006; 69: 1461-1467.
28. Scheidel LM, Stollar V. Mutations that confer resistance to mycophenolicacid and ribavirin on Sindbis virus map to the nonstructural protein nsPl. Virology 1991; 181: 490- 499.
29. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003; 308: 37-47.
30. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl. 1): S65-S73.